Deutsche Bank has repeated a 'buy' rating for Creo Medical Group PLC (AIM:CREO, OTC:CMEOF) following a 'capital markets day' showcase that highlighted growing commercial traction and strong clinician support for its energy-based endoscopy platform.
The German bank said live presentations from physicians actively using Creo devices brought the opportunity into sharp view, highlighting both the ease of integration into existing workflows and the platform’s expanding clinical utility.
While no new financials were issued, management reiterated confidence in meeting FY25 expectations, the broker noted.
DB's buy rating comes with a 40p price target, which suggests some major upside from the current share price in London, around 10.25p.
Looking ahead, the German bank pointed to several supportive drivers: a large and growing addressable market, positive surgeon feedback, and a broader suite of products scheduled for release between late 2026 and early 2027.
It also flagged potentially significant upside in the US market from 2027, notably through the anticipated CPT reimbursement code and ongoing studies with Intuitive and MicroBlate.
Creo remains well-funded and strategically positioned for material long-term upside, the DB analyst noted, whilst pointing out that guidance is now set more prudently (management is targeting break-even by 2028).